Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

The Unpredictable Progression of PH1

This handout details the potential progressive decline of kidney function in PH1, which mostly results in end-stage kidney disease.

Impact of Long-Term Blood Pressure Variability on Adverse Cardiovascular Outcomes in High- and Low-Risk Populations

ATTR Amyloidosis Disease State Handout

This handout provides an overview of ATTR amyloidosis manifestations and the diagnostic tools that can be used to assess their presentation.

Zilebesiran in combination with a standard-of-care antihypertensive in patients with inadequately controlled hypertension: Primary results from the phase 2 KARDIA-2 study

Musculoskeletal Manifestations Associated with ATTR Amyloidosis

This slide deck provides disease education on ATTR amyloidosis, focusing on the musculoskeletal manifestations associated with the disease and their importance for early diagnosis and patient care.

Neurofilament Light Chain in ATTR Amyloidosis with Cardiomyopathy: Analysis from the Phase 3 APOLLO-B Study

Effect and Safety of Patisiran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy and Chronic Kidney Disease Results

Symptoms and Disease Burden of ATTR

This slide deck provides an overview of the symptoms and disease burden of ATTR.

The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease

GRAPHICAL ABSTRACT: KARDIA-3 Study Design: Zilebesiran as Add-On Therapy in Patients with High Cardiovascular Risk and Hypertension Inadequately Controlled by Standard of Care Antihypertensives

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.